Value Microcaps Zip Code Changers

[Bobwins]

ATE.v/ATBPF -.01 to C$.27

TORONTO--(BUSINESS WIRE)--February 26, 2018--Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE,
OTCQB: ATBPF) would like to confirm the previously announced timing for its Phase 2B double-blind clinical trial of ATB-346. The
final subject has now completed treatment and the subsequent two-week monitoring period. The CRO conducting the study, Topstone
Research Inc. (“Topstone”), is currently performing data validation and analysis. Antibe remains on its previously announced schedule
and anticipates being in a position to report top-line results during the week of March 19th, 2018.
The study was conducted in 240 healthy volunteers and is designed to demonstrate the unequivocal superiority of ATB-346 in
gastrointestinal (“GI”) safety compared to naproxen, the most prescribed nonsteroidal anti-inflammatory drug (“NSAID”) in the USA.
About ATB-346
ATB-346 is a hydrogen sulfide-releasing derivative of naproxen. NSAIDs are the most commonly used therapy for osteoarthritis, yet
their use is associated with a high incidence of gastrointestinal ulceration and bleeding. NSAIDs are also widely used in a number of
conditions, including rheumatoid arthritis, ankylosing spondylitis, and general pain reduction, with a similarly high rate of
gastrointestinal ulceration and bleeding. It is well-accepted that patients with these conditions would benefit greatly from an effective,
GI-sparing anti-inflammatory/analgesic agent such as ATB-346.
About Antibe Therapeutics Inc.
Antibe develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing
molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug ATB-346 targets the global need for a
safer, non-addictive drug for chronic pain and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets the urgent global
need for a non-addictive analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin.
www.antibethera.com.
Antibe’s subsidiary, Citagenix Inc. (“Citagenix”), is a leader in the sales and marketing of tissue regenerative products servicing the
orthopedic and dental marketplaces. Since its inception in 1997, Citagenix has become an important source of knowledge and
experience for bone regeneration in the Canadian medical device industry. Citagenix is active in 15 countries, operating in Canada
through its direct sales teams, and internationally via a network of distributor partnerships. www.citagenix.com.